InnoCare Pharma and Zenas BioPharma Announce License Agreement
Palo Alto – October 8, 2025 – Cooley advised InnoCare Pharma, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class and best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide, on its transformational license agreement with Zenas BioPharma, granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology. Under…

